Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy
Adir Shaulov, Chezi Ganzel, Noam Benyamini, Yossef Barshay, Neta Goldschmidt, David Lavie, Diana Libster, Alex Gural, Batia Avni, Moshe E. Gatt*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
3Scopus
citations
Fingerprint
Dive into the research topics of 'Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy'. Together they form a unique fingerprint.